Table 1.
A summary of multifunctional nanoparticles for cancer immunotherapy.
| Material | Delivery agents | Size | Targeting ligand | Function | In vitro/in vivo | Ref. |
|---|---|---|---|---|---|---|
| Liposome | B16 melanoma antigens/IFN-γ or lipopolysaccharide | Not reported | CD11c-ScFv or DEC-205-ScFv | Targeted vaccine/Co-delivery of antigen and danger signal | In vitro and in vivo | 20 |
| PLGA | Melanoma antigen tyrosinase-related protein 2(TRP2); toll-like receptor (TLR) ligand(7-acyl lipid A) | 350–410 nm | No | Co-delivery of antigen and TLR4 ligand | In vitro and in vivo | 21 |
| Polybutyl cyanoacrylate (PBCA) | CMV-β-gal plasmid/TGF-β siRNA | Not reported | No | gene delivery | In vivo | 22 |
| PLGA | Tumor antigenic peptide | 150–500 nm | No | Delivery of tumor antigenic peptides | In vitro and in vivo | 23 |
| Chitosan | Interleukin-12-encoded plasmid | 103–170 nm | Mannose | Targeted gene vaccine delivery | In vitro and in vivo | 24 |
| P(MDS-co-CES) | PTX, Interleukin-12-encoded plasmid PTX, Bcl-2 siRNA | 180 nm | No | Co-delivery of gene and drug | In vitro and in vivo | 25,26 |
| PEG-AuNPs | anti-VEGF siRNA (labeled with Alexa Fluor 488) | 20–26 nm | M2 peptide (TAMs-targeting peptide) | Dual Targeted Immunotherapy | In vitro and in vivo | 27 |